Skip to Content
Merck
All Photos(2)

Key Documents

View All Documentation

700064P

Avanti

cholestanol

Avanti Research™ - A Croda Brand

Synonym(s):

b-Cholestanol; Dihydrocholesterol; Zymostanol; Cholestan-3b-ol; Dihydrocholesterin; 110828

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C27H48O
CAS Number:
80-97-7
Molecular Weight:
388.67
UNSPSC Code:
12352211
NACRES:
NA.25

description

5α-cholestan-3β-ol

Assay

>99% (TLC)

form

powder

packaging

pkg of 1 × 5 mg (700064P-5mg)

manufacturer/tradename

Avanti Research™ - A Croda Brand

shipped in

dry ice

storage temp.

−20°C

SMILES string

[H][C@@]12[C@]([C@](CC[C@H](O)C3)(C)C3CC2)([H])CC[C@@]4(C)[C@@]1([H])CC[C@]4([H])[C@]([H])(C)CCCC(C)C

InChI

1S/C27H48O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h18-25,28H,6-17H2,1-5H3

InChI key

QYIXCDOBOSTCEI-UHFFFAOYSA-N

General description

Cholestanol is a 5α-dihydro derivative of cholesterol. It acts as a marker for cholesterol absorption. Cholestanol is a steroid with 27 carbon atoms.

Packaging

5 mL Amber Glass Screw Cap Vial (700064P-5mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Cholestanol metabolism in patients with cerebrotendinous xanthomatosis: absorption, turnover, and tissue deposition
Bhattacharyya AK, et al.
Journal of Lipid Research, 48(1), 185-192 (2007)
Addictive Substances and Neurological Disease: Alcohol, Tobacco, Caffeine, and Drugs of Abuse in Everyday Lifestyles, 184(2), 247-254 (2017)
Michel R Hoenig et al.
Atherosclerosis, 184(2), 247-254 (2005-10-12)
Statins have been the mainstay of lipid-lowering therapy since their introduction. However, as lower LDL cholesterol targets are sought, adjunct therapies are becoming increasingly important. Few patients reach new targets with statin monotherapy. We propose that the cholestanol:cholesterol ratio can

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service